<html>
 <body>
  <div class="col-md-12" id="content" style="">
   <div class="hidden" data-drupal-messages-fallback="">
   </div>
   <div class="widget block" id="block-medsites-page-title">
    <h1>
     <span property="schema:name">
      Anticoagulation
     </span>
    </h1>
   </div>
   <div class="widget block" id="block-medsites-content">
    <article about="/commodorecompendium/anticoagulation" data-history-node-id="1024" role="article" typeof="schema:WebPage">
     <div>
      <div class="field field--name-body field--type-text-with-summary field--label-hidden field__item" property="schema:text">
       <div class="WordSection1">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Anticoagulation – Madeleine Turcotte
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
       </div>
       <p>
       </p>
       <div class="WordSection2">
        <table class="GridTable411" style="border-collapse:collapse; border:none" width="97%">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
      <th>3</th>
      <th>4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Agent</td>
      <td>Dose</td>
      <td>Renal Dose</td>
      <td>Prophylaxis</td>
      <td>Monitoring</td>
    </tr>
    <tr>
      <td>Unfractionated heparin</td>
      <td>80 U/kg bolus, then 18 U/kg/hr</td>
      <td>No change necessary</td>
      <td>5000 U q8 hr</td>
      <td>PTT (automatic in order set)</td>
    </tr>
    <tr>
      <td>Enoxaparin (Lovenox)</td>
      <td>1 mg/kg q 12 hr</td>
      <td>1 mg/kg daily</td>
      <td>40 mg daily  or 30 mg BID</td>
      <td>LMWH level (anti-Xa level) Best checked 4 hr after 4th dose</td>
    </tr>
    <tr>
      <td>Warfarin (Coumadin)</td>
      <td>Start 2-5mg daily and monitor INR Can consult Pharmacy</td>
      <td>No change necessary</td>
      <td>NaN</td>
      <td>PT/INR Use Chromogenic Factor X assay if pt has APLS</td>
    </tr>
    <tr>
      <td>Dabigatran (Pradaxa)</td>
      <td>After 5 days of a parenteral AC, 150 mg BID</td>
      <td>Avoid use</td>
      <td>NaN</td>
      <td>Can test drug level if concerned (Any DOAC)</td>
    </tr>
    <tr>
      <td>Rivaroxaban (Xarelto)</td>
      <td>15 mg BID x21 d then 20 mg daily</td>
      <td>Avoid use in CrCl&lt;30</td>
      <td>10mg QD</td>
      <td>NaN</td>
    </tr>
    <tr>
      <td>Apixaban (Eliquis)</td>
      <td>10mg BID x7d, then 5mg BID</td>
      <td>VTE: No adjustment</td>
      <td>2.5 mg BID</td>
      <td>A Fib: 2.5mg BID, if 2 of the following: Cr 1.5, Age &gt; 80 Weight &lt; 60kg</td>
    </tr>
    <tr>
      <td>Edoxaban (Savaysa)</td>
      <td>After 5 days of a parenteral AC, 60 mg daily</td>
      <td>30 mg for CrCl 15-50 Avoid if CrCl &gt; 95</td>
      <td>NaN</td>
      <td>Best studied option in renal dysfunction</td>
    </tr>
  </tbody>
</table>
        </table>
        <p>
        </p>
        <table align="left" class="TableGrid3" style="width:100.0%; border-collapse:collapse; border:none; margin-left:9px; margin-right:9px" width="100%">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NOAC/DOAC</td>
      <td>Warfarin</td>
    </tr>
    <tr>
      <td>Quick onset/offset, fixed dosing</td>
      <td>Antidote/reversal agent available</td>
    </tr>
    <tr>
      <td>Reduced incidence of hemorrhagic stroke</td>
      <td>Measurable levels of anticoagulation effect</td>
    </tr>
    <tr>
      <td>Fewer drug interactions, no food interaction</td>
      <td>Strongest evidence in patients with ESRD</td>
    </tr>
    <tr>
      <td>No need for routine monitoring</td>
      <td>Lower risk of GI bleeding (varies)</td>
    </tr>
    <tr>
      <td>Monthly cost $350-450 but discounts available</td>
      <td>Monthly cost: $4</td>
    </tr>
  </tbody>
</table>
        </table>
        <p>
        </p>
        <p>
         <span style="page:WordSection2">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="tab-stops:9.0pt">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Additional Information
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 VA favors dabigatran among DOACs
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Dabigatran cannot be stored in a pill box
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   PADR for apixaban citing “patient uses a pillbox and cannot use dabigatran”
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Concomitant Malignancy: favor LMWH, can also use apixaban
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Renal dysfunction: favor warfarin, apixaban or edoxaban
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Hx of GI bleed: avoid dabigatran, rivaroxaban, edoxaban (may have higher risk of GI bleed)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Pregnancy: LMWH (other agents may cross the placenta)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <table align="left" class="TableGrid3" style="width:100.0%; border-collapse:collapse; border:none; margin-left:9px; margin-right:9px" width="100%">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Indication</td>
      <td>Agent / Duration</td>
      <td>Other Notes</td>
    </tr>
    <tr>
      <td>VTE</td>
      <td>Any agent Duration: See VTE section</td>
      <td>See Deciding between Agents</td>
    </tr>
    <tr>
      <td>Atrial Fib (non-valvular)</td>
      <td>Apixaban or dabigatran Duration: Indefinite CHADSVASc &gt; 2, Consider if score of 1</td>
      <td>All DOACs: ↓ rates of ICH Apixaban &amp; dabigatran: superior to warfarin in preventing stroke</td>
    </tr>
    <tr>
      <td>Artificial Heart Valves</td>
      <td>Warfarin Target INR depends on type of valve If the pt has concurrent Afib, may need higher INR goal  Duration: Mechanical, Indefinite Surgically placed bioprosthetic, 3-6 months</td>
      <td>DOACs contraindicated with mechanical valves! Bioprosthetic valves: DOACs okay if coexisting indication  No AC after TAVR unless patient has other indication</td>
    </tr>
    <tr>
      <td>ACS</td>
      <td>PCI: Heparin or LMWH until PCI Fibrinolytic: 2-8 days after fibrinolysis</td>
      <td>If other indication for AC, assess bleeding/thrombosis risks to determine AC/Antiplatelet combination</td>
    </tr>
    <tr>
      <td>ACS</td>
      <td>No PCI: rivaroxaban 2.5 mg BID for 1 year, then reassess risk/benefit</td>
      <td>If other indication for AC, assess bleeding/thrombosis risks to determine AC/Antiplatelet combination</td>
    </tr>
    <tr>
      <td>LV Thrombus</td>
      <td>Warfarin superior Duration: At least 3 months</td>
      <td>AC can also be considered in patients with MI who are at high risk for LV thrombus: LVEF &lt;30% w/ antero-apical wall motion abnormalities</td>
    </tr>
    <tr>
      <td>Portal Vein Thrombus</td>
      <td>Any agent DOAC preferred In cirrhosis (INR may not reflect level of anticoagulation) Duration: 3-6 months, or indefinitely if pt has permanent thrombotic risk factors</td>
      <td>Consider bleeding risk: large esophageal varices</td>
    </tr>
    <tr>
      <td>Thrombophilia</td>
      <td>Any agent (DOACs less effective in APS) Duration: 6 months after any thrombosis Lifelong if recurrent, life-threatening, or unprovoked</td>
      <td>Antiphospholipid antibody syndrome: lifelong warfarin for any thrombosis that is otherwise unprovoked</td>
    </tr>
  </tbody>
</table>
        </table>
        <p>
        </p>
        <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:107%">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="line-height:107%">
                 <span style="font-family:Palatino">
                 </span>
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
         <p style="border:none; padding:0in">
         </p>
         <p style="border:none; padding:0in">
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:107%">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="line-height:107%">
                 <span style="font-family:Palatino">
                  Transitioning Between Anticoagulants with DOACs
                 </span>
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <ul>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                LMWH
                <span style="color:black">
                 to Warfarin
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Warfarin and LMWH given simultaneously until INR is therapeutic for 24 hours
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Warfarin
                <span style="color:black">
                 to DOAC
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Start
                   <span style="color:black">
                    DOAC when INR < 2.0
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                DOAC
                <span style="color:black">
                 to Warfarin
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   High Risk DVT/PE – start LMWH or UFH, then start Warfarin
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Low to Moderate Risk DVT/PE – Start warfarin while patient on DOAC, Stop DOAC on Day 3 of warfarin therapy, Check INR on day 4
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                LMWH
                <span style="color:black">
                 to DOAC
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Stop LMWH and start DOAC when due for next dose of LMWH (within 2 hrs)
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                DOAC
                <span style="color:black">
                 to LMWH
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Stop
                   <span style="color:black">
                    DOAC and start LMWH when due for next DOAC dose
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                UFH
                <span style="color:black">
                 to DOAC
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Start
                   <span style="color:black">
                    DOAC when IV stopped (30 min prior to cessation if high risk for thrombosis)
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   DOAC
                   <span style="color:black">
                    to UFH
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection2">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Start IV heparin with bolus when next DOAC dose is due
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
       </div>
       <p>
       </p>
       <div class="WordSection3">
       </div>
       <p>
       </p>
       <div class="WordSection4">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection4">
           <span style="font-size:11pt">
            <span style="line-height:107%">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="line-height:107%">
                 <span style="font-family:Palatino">
                  Peri-Procedural Management of Anticoagulation
                 </span>
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <ul>
         <li>
          <span style="page:WordSection4">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Temporary IVC filter indicated in pts with very recent acute VTE (within 3-4 weeks) if the procedure requires AC delay >12 hours
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection4">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  For those at high risk of thromboembolism:
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection4">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Consider continuing AC for low-bleeding-risk procedures, i.e. dental procedures, cutaneous biopsy/excision, ICD placement, endovascular procedures.
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection4">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Can bridge with LMWH or heparin drip
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
        <p>
        </p>
        <table class="Table" style="background:white; border-collapse:collapse">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NaN</td>
      <td>Stop before procedure</td>
      <td>Restart after procedure</td>
    </tr>
    <tr>
      <td>Warfarin</td>
      <td>5 days prior, check INR day of</td>
      <td>12 to 24 hours after</td>
    </tr>
    <tr>
      <td>Dabigatran</td>
      <td>One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)</td>
      <td>1 day after (2 days if high bleeding risk)</td>
    </tr>
    <tr>
      <td>Rivaroxaban</td>
      <td>One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)</td>
      <td>1 day after (2 days if high bleeding risk)</td>
    </tr>
    <tr>
      <td>Apixaban</td>
      <td>One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)</td>
      <td>1 day after (2 days if high bleeding risk)</td>
    </tr>
    <tr>
      <td>Edoxaban</td>
      <td>One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)</td>
      <td>1 day after (2 days if high bleeding risk)</td>
    </tr>
    <tr>
      <td>Heparin</td>
      <td>Stop infusion 4-5 hours prior</td>
      <td>24 hours after</td>
    </tr>
    <tr>
      <td>Enoxaparin</td>
      <td>24 hours prior (hold evening dose if BID dosing, give half of AM dose if daily dosing)</td>
      <td>24 hours after, (48-72 hours if high bleeding risk)</td>
    </tr>
  </tbody>
</table>
        </table>
       </div>
       <p>
       </p>
       <div class="WordSection5">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection5">
           <span style="font-size:11pt">
            <span style="line-height:107%">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="line-height:107%">
                 <span style="font-family:Palatino">
                  Strategies for Reversal of Anticoagulation
                 </span>
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <p>
         <span style="page:WordSection5">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="tab-stops:9.0pt">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Warfarin
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li style="margin-top:1px">
          <span style="page:WordSection5">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Vitamin
                 <span style="color:black">
                  K: onset at 12 hours but takes 24-48 hrs for full effect
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection5">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Life Threatening Bleeding: Give IV Vitamin K 10 mg over 30 minutes
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection5">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Intracranial
                   <span style="color:black">
                    bleed, bleed with hemodynamic instability, emergent procedure Non-life threatening
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
            <ul>
             <li>
              <span style="page:WordSection6">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="tab-stops:9.0pt">
                  <span style="font-family:Calibri,sans-serif">
                   <span style="font-size:12.0pt">
                    <span style="font-family:Palatino">
                     INR <5: Vitamin K not recommended
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection6">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="tab-stops:9.0pt">
                  <span style="font-family:Calibri,sans-serif">
                   <span style="font-size:12.0pt">
                    <span style="font-family:Palatino">
                     INR 5-10: Vitamin K 1-5 mg IV or PO
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection6">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="tab-stops:9.0pt">
                  <span style="font-family:Calibri,sans-serif">
                   <span style="font-size:12.0pt">
                    <span style="font-family:Palatino">
                     INR >10: Vitamin K 5mg PO or 5 mg IV
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
            </ul>
           </li>
          </ul>
         </li>
        </ul>
       </div>
       <ul>
        <li style="list-style-type:none">
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Prior to surgery
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul style="list-style-type:disc">
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Rapid reversal INR > 5: 5mg Vit K IV (24 hours prior to procedure)
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
           </ul>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  FFP
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul style="list-style-type:disc">
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   15 ml/kg (i.e. 4 units/70 kg person) if need reversal <24 hrs, plus give Vitamin K
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
           </ul>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  KCentra ($$$): Contains Factors II, VII, IX, and X with Protein C, Protein S, and heparin
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
           <ul style="list-style-type:disc">
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Given instead of plasma when insufficient time for plasma/Vit K to work
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Avoid giving this in HIT
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
            <li>
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   Administer with Vitamin K
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </li>
           </ul>
          </li>
         </ul>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="tab-stops:9.0pt">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              Dabigatran
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li style="margin-top:1px">
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="tab-stops:9.0pt">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Idarucizumab
               <span style="color:black">
                ($$$) will reverse if prolonged thrombin time – Consult Hematology
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="tab-stops:9.0pt">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Xa
              </span>
             </span>
            </span>
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              drugs
              <span style="color:black">
               (Rivaroxaban, apixaban, edoxaban)
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="tab-stops:9.0pt">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               FEIBA
               <span style="color:black">
                (Factor VIII inhibitor bypassing activity) – can promote coagulation but is not a reversal agent; limited data to support use
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="tab-stops:9.0pt">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               <span style="color:black">
                Consult Hematology before using; andexanet alfa is not yet available here
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
      </div>
     </div>
    </article>
   </div>
  </div>
 </body>
</html>